BridgeBio Pharma Inc (BBIO)
27.14
-0.72
(-2.58%)
USD |
NASDAQ |
Jun 17, 16:00
27.14
0.00 (0.00%)
After-Hours: 20:00
BridgeBio Pharma Debt to Equity Ratio: -1.635 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
March 31, 2024 | -1.635 |
December 31, 2023 | -1.275 |
September 30, 2023 | -1.425 |
June 30, 2023 | -1.262 |
March 31, 2023 | -1.398 |
December 31, 2022 | -1.361 |
September 30, 2022 | -1.492 |
June 30, 2022 | -1.651 |
March 31, 2022 | -1.641 |
December 31, 2021 | -1.958 |
Date | Value |
---|---|
September 30, 2021 | -1.85 |
June 30, 2021 | -2.959 |
March 31, 2021 | -3.453 |
December 31, 2020 | 8.243 |
September 30, 2020 | 2.882 |
June 30, 2020 | 1.756 |
March 31, 2020 | 1.212 |
December 31, 2019 | 0.2247 |
September 30, 2019 | 0.1632 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-3.453
Minimum
Mar 2021
8.243
Maximum
Dec 2020
-0.4673
Average
-1.398
Median
Mar 2023
Debt to Equity Ratio Benchmarks
Alnylam Pharmaceuticals Inc | -4.660 |
Pfizer Inc | 0.7445 |
Arcellx Inc | 0.00 |
Biomarin Pharmaceutical Inc | 0.2144 |
Viking Therapeutics Inc | -- |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 849.33M |
Total Liabilities (Quarterly) | 1.886B |
Shareholders Equity (Quarterly) | -1.050B |
Current Ratio | 5.538 |
Net Debt Paydown Yield | -0.03% |